RedHill Biopharma to Present Positive Phase II Results of BEKINDA® for IBS-D at Digestive Disease Week 2018
May 30, 2018 08:00 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel and RALEIGH, N.C., May 30, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty...
AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew and MedChew Products Throughout South Korea
April 03, 2018 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTCQB:AXIM), a world leader in cannabinoid research and development, today announced that it has...
Visualize Your Home With A TAMKO® Roof On HOVER®
January 09, 2018 11:04 ET
|
TAMKO Building Products, Inc.
Orlando, Florida, Jan. 09, 2018 (GLOBE NEWSWIRE) -- TAMKO Building Products, Inc. is excited to announce that its roofing products are now options in HOVER®’s product library, a platform that...
Meritage Homes to Unveil Pioneering reNEWable Living Home in Orlando
January 08, 2018 11:35 ET
|
Meritage Homes Corporation
PHOENIX, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Meritage Homes Corporation (NYSE:MTH), a leading U.S. homebuilder, today announced the completion of the reNEWable Living Home. In connection with BSB...
Axim Biotechnologies Announces Phase IIa Trial Results Validating its Proprietary Cannabinoid Delivery Method for Treatment of Irritable Bowel Syndrome (IBS)
November 21, 2017 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced clinical trial results...
AXIM Biotech to Present at Rodman & Renshaw 19th Annual Global Investment Conference in New York City
September 07, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company will be...
AXIM® Biotechnologies Secures Funding to Advance Clinical Trials and Bioequivalency Study
June 19, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, June 19, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company has...
AXIM Biotech Holds Annual Board Meeting
January 25, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Jan. 25, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, held its second annual board meeting on...
AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum
January 18, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Jan. 18, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating...
AXIM® Biotech Receives Positive PK Data Results for CanChew Plus® CBD Gum
January 04, 2017 09:00 ET
|
AXIM Biotechnologies, Inc
NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK)...